Association for Molecular Pathology                       
Newsletter                                                                
   
May 2009, Volume 15, Number 2 

Inside this Issue

Front Page
President's Message
Committee Reports
• Clinical Practice Committee
 Economic Affairs Committee
 Membership & Professional
  Development Committee

 Nominating Committee
 Professional Relations Committee
 Program Committee
 Publications Committee
 Training & Education Committee
Subdivision Reports
 Genetics
 Hematopathology
 Infectious Diseases
 Solid Tumors
Special Features
 AMP Leadership Award
 CHAMP

 Member Survey Report
 Web Editorial Board Report
 Show Me the Money!
 Announcements
 Career Opportunities
 Meetings and Upcoming Events
2009 AMP Officers and Appointees

Hematopathology Subdivision Report

Kojo S. J. Elenitoba-Johnson, MD By Kojo S. J. Elenitoba-Johnson, MD
Chair, Hematopathology Subdivision
e-mail: kojoelen@umich.edu

Tim Greiner and I have planned an exciting Hematopathology program for the 2009 AMP Annual Meeting. The program will be kicked off with Bryan Betz who will be speaking on mutations with prognostic significance in acute myelogenous leukemia in an Early Bird Session. The program will also feature two workshops. The first session will consist of a platform presentation of selected abstracts featuring exciting work that is being conducted by trainees and AMP members. The second Workshop will feature presentations discussing acquired mutations in myeloproliferative disorders. Joseph Prchal will speak about somatic mutations and uniparental disomy in Philadelphia chromosome negative myeloproliferative diseases. Rebecca McClure will discuss the practical issues associated with detection of JAK2 and other acquired mutations in chronic myeloproliferative disorders. The Plenary Session will address the increasingly recognized role of deregulated NFκB signaling in the pathogenesis of malignant lymphomas. In this session, Laura Pasqualucci will discuss the pathway alterations in diffuse large B-cell lymphoma and Vu Ngo will discuss discoveries enabled by the RNA interference (RNAi) screens for identification of molecular targets in lymphoma. The Hematopathology program promises to be very exciting. We look forward to some very interactive and informative sessions.